Haupt Pharma has successfully passed an FDA inspection at its site in Regensburg, Germany. Haupt Pharma Amareg completed the audit for four inspected solid and semi-solid, high-potent products. The inspection covered manufacturing and packaging, as well as development and analytics, with no form 483 issued.
"The management board congratulates Haupt Pharma Amareg on its successful completion of the FDA inspection. This result once again confirms the high quality standards within the group," said Dr. Karl Heinz Brücher, chief operating officer of Haupt Pharma. “The outstanding commitment of the entire team in Regensburg has contributed to this positive result.”